

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 6/5/1950
Gender: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Extractable Nuclear Antigen Antibodies (Smith/RNP, Smith, SSA 52, SSA 60, and SSB)

ARUP test code 0050652

Smith (ENA) Antibody, IgG 2 AU/mL (Ref Interval: 0-40)
INTERPRETIVE INFORMATION: Smith (ENA) Antibody, IgG

29 AU/mL or Less Negative
30 - 40 AU/mL Equivocal
41 AU/mL or Greater Positive

Smith antibody is highly specific (greater than 90 percent) for systemic lupus erythematosus (SLE) but only occurs in 30-35 percent of SLE cases. The presence of antibodies to Smith has variable associations with SLE clinical manifestations.

SSA-52 (Ro52) (ENA) Antibody, IgG 2 AU/mL (Ref Interval: 0-40)
INTERPRETIVE INFORMATION: SSA-52 (Ro52) (ENA) Antibody, IgG

29 AU/mL or Less Negative
30 - 40 AU/mL Equivocal
41 AU/mL or Greater Positive

SSA-52 (Ro52) and/or SSA-60 (Ro60) antibodies are associated with a diagnosis of Sjogren syndrome, systemic lupus erythematosus (SLE), and systemic sclerosis. SSA-52 antibody overlaps significantly with the major SSc-related antibodies. SSA-52 (Ro52) antibody occurs frequently in patients with inflammatory myopathies, often in the presence of interstitial lung disease.

SSA-60 (Ro60) (ENA) Antibody, IgG 1 AU/mL (Ref Interval: 0-40)
REFERENCE INTERVAL: SSA-60 (Ro60) (ENA) Antibody, IgG

29 AU/mL or Less Negative
30 - 40 AU/mL Equivocal
41 AU/mL or Greater Positive

Smith/RNP (ENA) Ab, IgG 2 Units (Ref Interval: 0-19)

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

INTERPRETIVE INFORMATION: Smith/RNP (ENA) Antibody, IgG

19 Units or Less Negative
 20 to 39 Units Weak Positive
 40 to 80 Units Moderate Positive
 81 Units or greater Strong Positive

Smith/RNP antibodies are frequently seen in patients with mixed connective tissue disease (MCTD) and are also associated with other systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus (SLE), systemic sclerosis, and myositis. Antibodies targeting the Smith/RNP antigenic complex also recognize Smith antigens, therefore, the Smith antibody response must be considered when interpreting these results.

SSB (La) (ENA) Antibody, IgG

0 AU/mL (Ref Interval: 0-40)

INTERPRETIVE INFORMATION: SSB (La) (ENA) Ab, IgG

29 AU/mL or Less Negative
 30 - 40 AU/mL Equivocal
 41 AU/mL or Greater Positive

SSB (La) antibody is seen in 50-60% of Sjogren syndrome cases and is specific if it is the only ENA antibody present. 15-25% of patients with systemic lupus erythematosus (SLE) and 5-10% of patients with progressive systemic sclerosis (PSS) also have this antibody.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Smith (ENA) Antibody, IgG	23-140-108336	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SSA-52 (Ro52) (ENA) Antibody, IgG	23-140-108336	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SSA-60 (Ro60) (ENA) Antibody, IgG	23-140-108336	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Smith/RNP (ENA) Ab, IgG	23-140-108336	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SSB (La) (ENA) Antibody, IgG	23-140-108336	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at: